Evidence map›Paper›PMID 40928725›Full record

ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

From neglected to notoriety: a review of Mpox clinical features, virology, epidemiology, treatment and prevention strategies.

Clément Viguier, Pierre Delobel, François-Xavier Lescure, Simon Bessis, Jean-Michel Mansuy, Guillaume Martin-Blondel

Abstract readReview
In one paragraph

Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Clément ViguierDepartment of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, 31059 Cedex 9, France.ORCID http://orcid.org/0000-0002-3270-178X
Pierre DelobelDepartment of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, 31059 Cedex 9, France.ORCID http://orcid.org/0000-0002-2874-3581
François-Xavier LescureDepartment of Infectious and Tropical Diseases, APHP, Bichat - Claude Bernard Hospital, Paris, France.ORCID http://orcid.org/0000-0002-2828-125X
Simon BessisBiology of Viral Emerging Infections, INSERM UMR5308, Institut Pasteur, Lyon, France.
Jean-Michel MansuyNEO-I3D Research Group, Toulouse University Hospital, Toulouse, France.ORCID http://orcid.org/0000-0002-4322-5061
Guillaume Martin-BlondelDepartment of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, 31059 Cedex 9, France. martin-blondel.g@chu-toulouse.fr.ORCID http://orcid.org/0000-0002-8363-7028

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis narrative review aims to provide an overview of current knowledge on mpox, emphasizing updated epidemiology and recent advances in treatment and prevention strategies, in light of the latest outbreaks.

methodsWe searched PubMed and Google Scholar for publications on 'Mpox' and 'Monkeypox' up to June 5, 2025. Grey literature from governmental and health agencies was also accessed for outbreak reports and guidelines where published evidence was unavailable.

resultsRecent outbreaks have redefined mpox epidemiology. Whereas previous regional outbreaks were mainly driven by zoonotic spillover with limited household transmission and often affecting children, more recent outbreaks have involved sustained human-to-human transmission. Such transmission has occurred among men who have sex with men for clade IIb and within heterosexual networks for clade Ib outbreaks, and more recently clade Ia outbreaks, primarily through sexual contact. Clinical features have also shifted toward more localized lesions, prominently in the anogenital area. While mpox is usually self-limited, severe cases may occur in pregnant women, young children, and immunocompromised individuals. Mpox management primarily relies on supportive care. In patients with severe mpox, or at risk of, tecovirimat was widely recognized as the first-line therapy, although it has failed to demonstrate its effectiveness in recent randomized controlled trials. The Modified Vaccinia Ankara vaccine (two-dose regimen) has shown a favorable safety profile and promising efficacy data in preventing clade IIb mpox, including immunocompromised individuals.

conclusionMpox has transitioned from a neglected zoonosis to a re-emerging global health threat. Sustained surveillance, robust and targeted public health interventions, and equitable access to diagnostics, vaccines, and antiviral treatments are critical to managing potential future mpox outbreaks.

Indexed as

Mpox, MonkeypoxAnimalsAntiviral AgentsDisease OutbreaksFemaleHumansMalePregnancyAntiviral AgentsAnti-viral treatmentEpidemiologyMonkeypox virusMpoxVaccination

Identifiers

PMID40928725
PMCPMC12619834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.